Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22022347 | 1.00 | CCR2 (0.35) | CCR2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL19787861 | 0.94 | KDM4E (0.33) | CYP1A2 | |
| SCHEMBL21191731 | 0.89 | CYP1A2 (0.36) | CCR2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL23634135 | 0.87 | CCR2 (0.38) | CCR2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL22023689 | 0.85 | CCR2 (0.40) | CCR2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL21191753 | 0.84 | CCR2 (0.35) | CCR2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL22570154 | 0.83 | CCR2 (0.32) | CCR2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL17307730 | 0.83 | CCR2 (0.32) | CCR2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL21707875 | 0.82 | PRCP (0.35) | CYP1A2 | |
| SCHEMBL23845837 | 0.81 | CCR2 (0.33) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, CYP3A5, UGT1A1 | CCR2 3490/4885SLC6A2 697/4885SLC6A4 1682/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CCR2 274/4885SLC6A2 3987/4885SLC6A4 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.